Cubist Systematic Strategies’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$506K Buy
6,500
+300
+5% +$23.4K ﹤0.01% 2276
2025
Q2
$485K Sell
6,200
-16,400
-73% -$1.22M ﹤0.01% 2259
2025
Q1
$1.64M Sell
22,600
-58,800
-72% -$4.21M 0.01% 1539
2024
Q4
$6.03M Buy
81,400
+12,200
+18% +$854K 0.04% 722
2024
Q3
$4.57M Buy
69,200
+67,200
+3,360% +$4.88M 0.03% 889
2024
Q2
$185K Sell
2,000
-16,200
-89% -$1.43M ﹤0.01% 2526
2024
Q1
$1.74M Sell
18,200
-44,500
-71% -$3.74M 0.01% 1760
2023
Q4
$4.78M Buy
62,700
+30,000
+92% +$2.09M 0.03% 898
2023
Q3
$2.27M Buy
32,700
+17,900
+121% +$1.44M 0.02% 1286
2023
Q2
$1.4M Sell
14,800
-45,800
-76% -$3.98M 0.01% 1756
2023
Q1
$5.01M Sell
60,600
-70,100
-54% -$5.51M 0.03% 925
2022
Q4
$9.75M Buy
130,700
+90,500
+225% +$6.97M 0.06% 498
2022
Q3
$3.32M Buy
40,200
+33,800
+528% +$3.25M 0.02% 1473
2022
Q2
$609K Buy
+6,400
New +$663K ﹤0.01% 2896

Other funds holding EW

Cubist Systematic Strategies's EW Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Edwards Lifesciences (EW) stake by 86% in Q3 2025, selling an estimated $5.31M and leaving 11,525 shares worth $896K. The position accounts for ﹤0.01% of the portfolio, ranked #1989.

Cubist Systematic Strategies first reported a position in EW in Q2 2014 and has held it in 41 quarters since. The position peaked at $26.1M in Q4 2022. 1,253 funds tracked by Wall St. Rank hold EW as of Q3 2025.

  • Cubist Systematic Strategies held 11,525 shares of Edwards Lifesciences worth $896K as of Q3 2025.
  • Cubist Systematic Strategies sold 67,978 Edwards Lifesciences shares in Q3 2025, an estimated $5.31M.
  • Edwards Lifesciences made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1989 holding.
  • Cubist Systematic Strategies first reported a position in Edwards Lifesciences in Q2 2014 and has held it in 41 quarters since.
  • Cubist Systematic Strategies's Edwards Lifesciences position peaked at $26.1M in Q4 2022.
  • 1,253 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.